Indaptus Therapeutics Financials

INDP Stock  USD 2.13  0.01  0.47%   
Based on the key indicators related to Indaptus Therapeutics' liquidity, profitability, solvency, and operating efficiency, Indaptus Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in August. At this time, Indaptus Therapeutics' Non Current Assets Total are relatively stable compared to the past year. As of 07/20/2024, Non Currrent Assets Other is likely to grow to about 843.3 K, while Net Debt is likely to drop (13.8 M). Key indicators impacting Indaptus Therapeutics' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.01910.0145
Significantly Up
Slightly volatile
Current Ratio3.885.0451
Way Down
Slightly volatile
The financial analysis of Indaptus Therapeutics is a critical element in measuring its lifeblood. Investors should not minimize Indaptus Therapeutics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.

Net Income

(16.19 Million)

Understanding current and past Indaptus Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Indaptus Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Indaptus Therapeutics' assets may result in an increase in income on the income statement.
The data published in Indaptus Therapeutics' official financial statements typically reflect Indaptus Therapeutics' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Indaptus Therapeutics' quantitative information. For example, before you start analyzing numbers published by Indaptus accountants, it's essential to understand Indaptus Therapeutics' liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
Please note, the imprecision that can be found in Indaptus Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Indaptus Therapeutics. Check Indaptus Therapeutics' Beneish M Score to see the likelihood of Indaptus Therapeutics' management manipulating its earnings.

Indaptus Therapeutics Stock Summary

Indaptus Therapeutics competes with Rezolute, Tempest Therapeutics, Forte Biosciences, ABVC Biopharma, and Pasithea Therapeutics. Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York. Indaptus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people.
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CUSIPM53644106 45339J105 M53644148 45828B100
Business AddressThree Columbus Circle,
IndustryHealth Care
BenchmarkDow Jones Industrial
Phone646 427 2727
CurrencyUSD - US Dollar

Indaptus Therapeutics Key Financial Ratios

Indaptus Therapeutics' financial ratios allow both analysts and investors to convert raw data from Indaptus Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Indaptus Therapeutics over time and compare it to other companies across industries.

Indaptus Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Indaptus Therapeutics's current stock value. Our valuation model uses many indicators to compare Indaptus Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Indaptus Therapeutics competition to find correlations between indicators driving Indaptus Therapeutics's intrinsic value. More Info.
Indaptus Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Indaptus Therapeutics' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Indaptus Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Indaptus Therapeutics Systematic Risk

Indaptus Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Indaptus Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Execute Function
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Indaptus Therapeutics correlated with the market. If Beta is less than 0 Indaptus Therapeutics generally moves in the opposite direction as compared to the market. If Indaptus Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Indaptus Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Indaptus Therapeutics is generally in the same direction as the market. If Beta > 1 Indaptus Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Indaptus Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Indaptus Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Indaptus Therapeutics growth as a starting point in their analysis.

Price Earnings To Growth Ratio


At this time, Indaptus Therapeutics' Price Earnings To Growth Ratio is relatively stable compared to the past year.

Indaptus Therapeutics July 20, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Indaptus Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Indaptus Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Indaptus Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Indaptus Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Indaptus Therapeutics's daily price indicators and compare them against related drivers.

Additional Tools for Indaptus Stock Analysis

When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.